{
    "clinical_study": {
        "@rank": "168077", 
        "acronym": "SENTIMAG", 
        "arm_group": {
            "arm_group_label": "Identification of sentinel node(s)", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The study is based on the identification of sentinel node(s) by SENTIMAG / SIENNA + in\n      addition to the usual method (blue and /or radioactive product). This is a feasibility study"
        }, 
        "brief_title": "IDENTIFICATION OF SENTINEL NODE(S) IN BREAST CANCER", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "BREAST CANCER", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "-  Identification of Sentinel node(s)\n\n             1. Step 1: Identification using the technique Nanocis Sub-areolar injection of\n                Tc99m-Nanocis \u00ae the day before or the day of surgery\n\n             2. Step 2: Identification using the technique SentiMag \u00ae / Sienna+ Injection Sienna +\n                \u2122 should be done just after induction of anesthesia and before the injection of\n                Patent Blue dye\n\n             3. Step 3: Identification using the technique of Patent Blue Dye or Lymphotropic dye\n                injection or Patent Blue is performed after induction of anesthesia, the injection\n                and production Sienna + \u2122, the operating theater by the surgeon\n\n        -  Detection of Sentinel node(s)\n\n             1. Step 1: probe SentiMag \u00ae (study)\n\n             2. Step 2: hand probe gamma radiation detection and / or colorimetric detection\n                (standard)\n\n        -  Sentinel node's excision of radioactive and / or blue and / or magnetic (colored\n           brown-brown)\n\n        -  After the procedure:\n\n      Characterization of the size and weight of lymph nodes, histological and / or molecular OSNA\n      and linking nodal status with the detection rate of sentinel nodes for each technique.\n\n      NB: In case of synchronous bilateral cancer, 2 records are possible"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with invasive breast cancer or microinfiltrant proven by cytology and\n             histo-or whatever the histological type\n\n          -  cT0/cT1/cT2 (up to 5 cm) CN0 clinical and / or ultrasound and without prior treatment\n             (chemotherapy or neoadjuvant hormone )\n\n          -  Age greater than or equal to 18\n\n          -  Reporting of breast surgery and axillary staging of sentinel lymph node\n\n          -  Using effective contraception (BHCG negative)\n\n          -  Patient affiliated with a health insurance\n\n          -  Consent signed by the patient\n\n        Exclusion Criteria:\n\n          -  T3 or T4 tumors (> 5 cm, cutaneous or muscle inflammation or cancer)\n\n          -  Presence of a clinically suspicious axillary adenopathy or imaging\n\n          -  Tumors bifocal or multifocal known before Surgery\n\n          -  History of breast surgery or axillary\n\n          -  Patient metastatic\n\n          -  Patient with a cons-indication anesthesia and / or surgery\n\n          -  Intolerance or hypersensitivity to the compounds or iron dextran or superparamagnetic\n             iron oxide or to Patent blue dye in centers where it is commonly used\n\n          -  Patient can not receive a radioactive isotope to the sentinel lymph node  resection\n\n          -  Allergy radioactive product\n\n          -  Chronic iron overload\n\n          -  Pacemaker or other implantable device in the chest wall\n\n          -  Failure to submit to medical study for geographical, social or psychological\n\n          -  Patient deprived of liberty or under guardianship\n\n          -  Pregnant or lactating"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "115", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790399", 
            "org_study_id": "SENTIMAG-1213"
        }, 
        "intervention": {
            "arm_group_label": "Identification of sentinel node(s)", 
            "description": "Excision of sentinel node(s) using SENTIMAG / SIENNA + in addition to the usual method (blue and /or radioactive product)", 
            "intervention_name": "Excision of sentinel node(s)", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "SENTINEL NODE", 
        "lastchanged_date": "March 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59020"
                    }, 
                    "name": "Centre Oscar Lambret"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35042"
                    }, 
                    "name": "Centre Eug\u00e8ne Marquis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31 052"
                    }, 
                    "name": "Institut Claudius Regaud"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vandoeuvre les nancy", 
                        "country": "France", 
                        "zip": "54 511"
                    }, 
                    "name": "Centre Alexis Vautrin"
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "IDENTIFICATION OF SENTINEL NODE(S) BY SENTIMAG\u00ae /SIENNA+ IN BREAST CANCER: FEASIBILITY STUDY", 
        "overall_official": {
            "affiliation": "Centre Oscar Lambret", 
            "last_name": "Jean-Louis MD HOUPEAU", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Idenfication 's rate of sentinel  nodes detected with new technical(SentiMag \u00ae / Sienna + TM)", 
            "measure": "Sentinel node(s)detected with new technical", 
            "safety_issue": "Yes", 
            "time_frame": "The day of surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790399"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Proportion of detected nodes for each method(standard and new)", 
            "measure": "Detected node(s) for each method(standard and new)", 
            "safety_issue": "Yes", 
            "time_frame": "The day of surgery"
        }, 
        "source": "Centre Oscar Lambret", 
        "sponsors": {
            "collaborator": {
                "agency": "Sysmex America, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Centre Oscar Lambret", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}